Equities Analysts Issue Forecasts for NovoCure Q4 Earnings

NovoCure Limited (NASDAQ:NVCR) – Investment analysts at HC Wainwright boosted their Q4 2025 EPS estimates for shares of NovoCure in a research note issued to investors on Tuesday, January 13th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will earn ($0.30) per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.08) EPS, FY2028 earnings at ($0.34) EPS and FY2029 earnings at $1.07 EPS.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, October 30th. The medical equipment provider reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The business had revenue of $167.20 million during the quarter, compared to analyst estimates of $158.81 million. NovoCure had a negative net margin of 27.66% and a negative return on equity of 50.29%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) earnings per share.

A number of other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. cut their price target on NovoCure from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Monday, October 27th. Wedbush reiterated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research note on Wednesday, October 8th. Finally, Evercore ISI set a $20.00 price target on NovoCure in a report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NovoCure has a consensus rating of “Hold” and an average price target of $25.50.

NovoCure Stock Up 0.2%

NVCR opened at $13.80 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. NovoCure has a fifty-two week low of $10.70 and a fifty-two week high of $27.47. The firm’s fifty day moving average is $12.71 and its 200 day moving average is $13.22. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -8.57 and a beta of 0.73.

Institutional Investors Weigh In On NovoCure

A number of hedge funds have recently made changes to their positions in the company. Soleus Capital Management L.P. boosted its stake in NovoCure by 25.0% during the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after buying an additional 1,382,888 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of NovoCure by 1,354.7% during the 2nd quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock worth $18,332,000 after acquiring an additional 959,079 shares in the last quarter. Millennium Management LLC raised its holdings in shares of NovoCure by 106.5% during the 3rd quarter. Millennium Management LLC now owns 1,335,490 shares of the medical equipment provider’s stock worth $17,255,000 after acquiring an additional 688,710 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in shares of NovoCure by 38.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,270,076 shares of the medical equipment provider’s stock valued at $40,407,000 after acquiring an additional 634,925 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of NovoCure by 2,063.2% in the third quarter. Dimensional Fund Advisors LP now owns 565,763 shares of the medical equipment provider’s stock valued at $7,310,000 after purchasing an additional 539,609 shares in the last quarter. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Piper Sandler reaffirmed a Buy on NVCR, signaling continued confidence in the company’s therapy adoption and longer‑term growth potential. Piper Sandler Remains a Buy on NovoCure (NVCR)
• Positive Sentiment: HC Wainwright still carries a Buy rating and a $39 price target and published a long‑range FY2030 EPS model projecting strong upside, supporting a bullish longer‑term view despite nearer‑term cuts. HC Wainwright Lowers NovoCure (NASDAQ:NVCR) Price Target to $39.00
• Neutral Sentiment: Wedbush reaffirmed a Neutral rating with an $18 price target (~30% above current levels), which could cap upside until clearer near‑term fundamentals emerge. Benzinga: Wedbush neutral on NovoCure
• Neutral Sentiment: Market consensus remains a Hold/Neutral across analysts, reflecting mixed views on timing of revenue progression vs. ongoing losses. NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for qualitative updates and investor Q&A but no immediate new financial guidance reported. NovoCure Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across multiple 2026 quarters and trimmed FY2026–2029 forecasts, signaling weaker near‑term profitability expectations that could pressure the stock until revenue trends accelerate. HC Wainwright Lowers NovoCure (NASDAQ:NVCR) Price Target to $39.00
• Negative Sentiment: Wells Fargo issued a Hold on NVCR, which removes a buy-side endorsement from a major desk and may limit near‑term retail/institutional buying momentum. NovoCure (NVCR) Gets a Hold from Wells Fargo

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.